Key Highlights

• Lunai Bioworks fell more than 20% on June 24 with no company-specific catalyst identified.

• The stock has lost approximately 81% over the prior year and 51% year-to-date despite a 63% one-month gain.

• Lunai recently repositioned from gene therapy to AI-driven therapeutics and biological defense systems.

• Extreme volatility reflects investor uncertainty around the company's corporate transformation.

Lunai Bioworks (NASDAQ:LNAI), formerly Renovaro Inc. and now applying artificial intelligence to advanced medical treatments and biological defense systems including its Neurotoxicity Intelligence Technology platform, fell more than 20% on June 24 with no company-specific catalyst as the stock continued to exhibit extreme volatility around its recent corporate repositioning.

The stock has lost approximately 81% over the prior twelve months and 51% year-to-date, yet recorded a gain of approximately 63% over the prior month, a combination that reflects the speculative and technically driven nature of trading in a company undergoing a fundamental strategic transformation. When a company pivots from one thematic category to another, early-phase investor interest often produces sharp momentum-driven rallies that are subsequently unwound as the market awaits evidence of execution.

Lunai's pivot from gene therapy to AI-driven therapeutics positions it at the intersection of two areas of active investor interest, artificial intelligence and biological defense systems, with the Neurotoxicity Intelligence Technology platform designed to address toxin detection and response. However, the pre-commercial stage of the repositioned business means the investment case rests on the credibility of the AI-therapeutics vision rather than near-term revenue delivery.

The June 24 session's decline extends the pattern of extreme two-directional volatility that has characterised the stock since the repositioning was announced.